Compare · ICCM vs SYK
ICCM vs SYK
Side-by-side comparison of IceCure Medical Ltd. (ICCM) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ICCM and SYK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK is the larger of the two at $112.48B, about 31563.7x ICCM ($3.6M).
- Over the past year, ICCM is down 95.7% and SYK is down 21.3% - SYK leads by 74.3 points.
- SYK has been more active in the news (8 items in the past 4 weeks vs 5 for ICCM).
- SYK has more recent analyst coverage (25 ratings vs 2 for ICCM).
- Company
- IceCure Medical Ltd.
- Stryker Corporation
- Price
- -
- -
- Market cap
- $3.6M
- $112.48B
- 1M return
- -47.12%
- +5.16%
- 1Y return
- -95.69%
- -21.34%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 5
- 8
- Recent ratings
- 2
- 25
IceCure Medical Ltd.
IceCure Medical Ltd develops and markets minimally invasive cryoablation therapies for women's health and oncology markets. It offers ProSense system, a cryoablation solution for breast tumors. The company was founded in 2006 and is headquartered in Caesarea, Israel.
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest ICCM
- SEC Form 6-K filed by IceCure Medical Ltd.
- IceCure Expands ProSense® ChoICE Study for Low-Risk Breast Cancer adding Legacy Health in Portland, OR as U.S. Clinical Site
- SEC Form 6-K filed by IceCure Medical Ltd.
- SEC Form 6-K filed by IceCure Medical Ltd.
- SEC Form 6-K filed by IceCure Medical Ltd.
- SEC Form 6-K filed by IceCure Medical Ltd.
- IceCure Medical Receives Regulatory Approval to Market ProSense® in China
- SEC Form 6-K filed by IceCure Medical Ltd.
- IceCure Signs Exclusive Distribution Agreement for ProSense® Cryoablation Systems in the Netherlands
- West Cancer Center Receives IRB Approval to Commence IceCure's ChoICE Study for Breast Cancer Cryoablation
Latest SYK
- Stryker launches Sonopet® 3, delivering greater power and precision in ultrasonic tissue removal
- Stryker and CMR Surgical announce strategic alliance to advance robotic-assisted surgery
- Barclays initiated coverage on Stryker with a new price target
- SEC Form 8-K filed by Stryker Corporation
- Stryker announces leadership succession
- Stryker to announce third quarter 2026 financial results
- VP, Chief Financial Officer Wells Preston Wendell disposed of 109 shares, decreasing direct ownership by 3% to 3,661 units (SEC Form 4)
- VP, Chief Financial Officer Wells Preston Wendell disposed of 2,739 shares, decreasing direct ownership by 42% to 3,770 units (SEC Form 4)
- Stryker showcases Foot & Ankle innovation at AOFAS 2026 with Prophecy® Surgical Planning for Incompass™ and Hoffmann® LRF smartHEX™
- New insider Baculik Emily Kay claimed ownership of 1,554 shares (SEC Form 3)